摘要
目的探讨奥美拉唑与抗血小板治疗对预防经皮冠状动脉介入术(PCI)后消化道出血和心血管事件效果。方法选择76例冠心病行PCI治疗患者为研究对象。采用随机数字表法分为对照组38例,观察组38例。对照组仅实施抗血小板治疗,观察组在对照组基础上加用奥美拉唑。比较两组患者消化道出血及心血管事件发生率。结果治疗前,两组患者血小板聚集率(PA)差异无统计学意义,经治疗后均有变化,但是两组差异无统计学意义(P>0.05);与对照组比较,观察组治疗后心血管事件发生率差异无统计学意义(χ2=1.910,P=0.167),消化道出血发生率明显较对照组低(χ2=8.296,P=0.004)。结论 PCI术后在抗血小板聚集治疗基础上加奥美拉唑,可有效降低消化道出血发生率,不会对血小板聚集率造成影响,不增加心血管事件风险。
Objective To explore the effect of omeprazole combined antiplatelet therapy for gastrointestinal bleeding and cardiovascular events after Percutaneous Coronary Intervention （PCI） in patients with coronary heart diease. Methods Seventy-six patients with coronary heart disease in treatment with PCI were selected and randomly divided into control group （38 cases） and observation group（38 cases）. Patients in control group were given antiplatelet therapy, and patients in observation group were given omeprazde combined antiplatelet. The gastrointestinal bleeding and cardiovascular events of two groups were observed. Results Before treatment,the of platelet aggregation rate （PA） of two groups was no significant differences （ P 〉 0. 05 ）. After treatment, the PA of two groups were significantly decreased （P 〈 0.05 ）, but there were no significant difference（P 〉 0.05 ）. The rate of cardiovascular events of two groups was no significant differences （χ^2 = 1. 910, P = 0. 167）, and the gastrointestinal bleeding rate of observation group was significantly lower than that of control group （χ^2 = 8. 296, P = 0. 004）. Conclusion Omeprazole combined antiplatelet therapy after percutaneous coronary intervention could effectively reduce gastrointestinal bleeding rate without decreased platelet aggregation rate and increased the risk of cardiovascular events.
出处
《中国临床保健杂志》
CAS
2017年第1期74-76,共3页
Chinese Journal of Clinical Healthcare
基金
浙江省医药卫生一般研究计划项目(2014-KYA005)
关键词
血管成形术
气囊
冠状动脉
胃肠出血
奥美拉唑
血小板聚集抑制剂
Angioplasty, balloon, coronary
Gastrointestinal hemorrhage
Omeprazole
Platelet aggregation inhibitors
